⚠ BETA β€” all market data shown (deals, filings, prices, indices) is demo / illustrative, not live trading data. For evaluation only; verify before acting.
June 17, 2026

NSE

Krishna Institute of Medical Sciences LimitedKIMS

Nifty Smallcap 250

Krishna Institute of Medical Sciences Limited (KIMS) is a healthcare provider in India, known for its medical education and research facilities.

Key productsMedical education, healthcare services
GeographyIndia
CompetitorsManipal Education & Healthcare, Apollo Hospitals Enterprises

AI-generated overview β€” verify before relying on it.

Net institutional flow

+β‚Ή0 Cr

Institutional buyers

1 in / 1 out

High-impact filings

1 Β· tilt Neutral

Next corporate action

β€”

Competitive landscape β€” the read

vs mapped peers Β· 1Y
Institutional money is backing ACUTAAS hardest (+β‚Ή98.2 Cr net). KIMS ranks #2 of 9 on flow (net buying +β‚Ή0 Cr). News & social buzz is most positive on ACUTAAS.
#CompanyInst. flow β‚ΉCrDealsHi-impactFiling mom.BuzzNews
1ACUTAAS+β‚Ή98.2 Cr1β€”β€”+46
2KIMSThis+β‚Ή0 Cr61β€”β€”β€”
3ACMESOLARβ€”β€”β€”β€”+36
4AADHARHFCβ€”β€”β€”β€”β€”β€”
5AARTIINDβ€”β€”β€”β€”β€”β€”
6ACE+β‚Ή0 Cr2β€”β€”β€”β€”
7AAVASβˆ’β‚Ή1.9 Cr2β€”β€”β€”β€”
8ABFRLβˆ’β‚Ή142.6 Cr4β€”β€”β€”β€”
9ABLBLβˆ’β‚Ή314.4 Cr29β€”β€”β€”β€”

Ranked by net institutional flow (buys βˆ’ sells, β‚ΉCr). Filing momentum = bullish βˆ’ bearish filings; Buzz = news+social sentiment. Curate peers in the company admin.

Timeline β€” KIMS day by day

  1. 2026-06-16FilingQualified institutions placement of equity shares of face value ₹ 2 each (the Equity Shares ) by KrishnGeneral
  2. 2026-06-16FilingAudited Standalone and Consolidated Financial Statements for the Financial Year ended 31st March 2026.Results
  3. 2026-06-13FilingKrishna Institute of Medical Sciences Limited has informed the Exchange regarding Outcome of Board Meeting helBoard Meeting
  4. 2026-06-11FilingDr. Bhaskara Rao Bollineni has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) read withShareholding Disclosure
  5. 2025-09-05BlockSELL Β· β‚Ή18.1 CrGOLDMAN SACHS (SINGAPORE) PTE - ODI
  6. 2025-09-05BlockBUY Β· β‚Ή18.1 CrGOLDMAN SACHS BANK EUROPE SE - ODI
  7. 2025-09-02BlockSELL Β· β‚Ή36.5 CrGOLDMAN SACHS (SINGAPORE) PTE - ODI
  8. 2025-09-02BlockBUY Β· β‚Ή36.5 CrGOLDMAN SACHS BANK EUROPE SE - ODI
  9. 2025-08-29BlockSELL Β· β‚Ή18.6 CrGOLDMAN SACHS (SINGAPORE) PTE - ODI
  10. 2025-08-29BlockBUY Β· β‚Ή18.6 CrGOLDMAN SACHS BANK EUROPE SE - ODI

Merged from deals, filings, corporate actions and news β€” newest first. Compact rolls each day up to net flow + counts. Scope with the range above.

Filings that matter

  • 2
    GeneralNeutral

    Qualified institutions placement of equity shares of face value ₹

    Source PDF β†’
  • 7
    ResultsNeutral

    Audited FY26 results likely provide a clear financial health snapshot.

    Source PDF β†’
  • 2
    Board MeetingNeutral

    Board meeting outcome routine; no significant share-price impact.

    Source PDF β†’
  • 2
    Shareholding DisclosureNeutral

    a copy of Disclosure under Regulation 31(4) read with Regulation 31(5) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

    Source PDF β†’

Bulk & block deals

6 deals Β· 2025-08-29 β†’ 2025-09-05

DateCounterpartyTypeSideValue
2025-09-05GOLDMAN SACHS (SINGAPORE) PTE - ODIHNI / otherSELLβ‚Ή18.1 Cr
2025-09-05GOLDMAN SACHS BANK EUROPE SE - ODIHNI / otherBUYβ‚Ή18.1 Cr
2025-09-02GOLDMAN SACHS (SINGAPORE) PTE - ODIHNI / otherSELLβ‚Ή36.5 Cr
2025-09-02GOLDMAN SACHS BANK EUROPE SE - ODIHNI / otherBUYβ‚Ή36.5 Cr
2025-08-29GOLDMAN SACHS (SINGAPORE) PTE - ODIHNI / otherSELLβ‚Ή18.6 Cr
2025-08-29GOLDMAN SACHS BANK EUROPE SE - ODIHNI / otherBUYβ‚Ή18.6 Cr

6 deals in the selected window β€” corporate actions are scoped to the same period. ~2 years of history available.

Results & transcripts

News & chatter on KIMS

RSS News

0

No recent news.

Google News RSS β€” links open the source.

Investdesk

0

No articles yet.

Our coverage.

Reddit

0

No Reddit chatter.

r/ posts mentioning the company.

Twitter / X

0

No posts.

Posts mentioning the company.